Phenotypes associated with this allele

• Allele Symbol: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}
• Allele Name: targeted mutation 1, Andrew P McMahon
• Allele ID: MGI:3576373
• Summary: 25 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Atoh1^tm3Hzo/Atoh1^+ Gt(ROSA)26Sor^tm1(cre/ERT)Nat/Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc	involves: 129 * 129S7/SvEvBrd * 129X1/SvJ	MGI:4420943
cn2	Atoh1^tm3Hzo/Atoh1^tm1Hzo Gt(ROSA)26Sor^tm1(cre/ERT)Nat/Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc	involves: 129 * 129S7/SvEvBrd * 129X1/SvJ	MGI:4420935
cn3	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc Olig2^tm2(TVA,cre)Rth/Olig2^+	involves: 129 * 129X1/SvJ	MGI:3810318
cn4	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^tm2(EGFP/cre)Alj Pgbd5^tm1.1Aken/Pgbd5^tm1.1Aken	involves: 129 * C57BL/6J * C57BL/6NTac * SW	MGI:7616743
cn5	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^+ Hk2^tm1.1Uku/Hk2^tm1.1Uku Tg(GFAP-cre)25Mes/0	involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N	MGI:5571383
cn6	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^+ Hk2^tm1.1Uku/Hk2^+ Tg(GFAP-cre)25Mes/0	involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N	MGI:5571384
cn7	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc Shh^tm2(cre/ERT2)Cjt/Shh^+	involves: 129S6/SvEvTac * 129X1/SvJ	MGI:3810321
cn8	Gli1^tm3(cre/ERT2)Alj/Gli1^+ Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc	involves: 129S6/SvEvTac * 129X1/SvJ	MGI:3810320
cn9	Gli1^tm3(cre/ERT2)Alj/Gli1^+ Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^+	involves: 129S6/SvEvTac * 129X1/SvJ	MGI:6197800
cn10	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^+ Nkx3-2^tm1(cre)Wez/Nkx3-2^+	involves: 129S7/SvEvBrd * 129X1/SvJ	MGI:5518633
cn11	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^+ Ndor1^Tg(UBC-cre/ERT2)1Ejb/0	involves: 129S/SvEv * 129X1/SvJ * C57BL/6	MGI:6197802
cn12	Gli2^tm1(cre/ERT2)Tipe/Gli2^+ Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^+	involves: 129X1/SvJ	MGI:6197798
cn13	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc Tlx3^tm1(cre)Qima/Tlx3^+	involves: 129X1/SvJ	MGI:3810319
cn14	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/? Tg(CAG-cre/Esr1*)5Amc/?	involves: 129X1/SvJ * C57BL/6 * CBA	MGI:3716204
cn15	Cdcp1^tm1.2Moas/Cdcp1^tm1.2Moas Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^+ Tg(KRT14-cre/ERT)20Efu/0	involves: 129X1/SvJ * C57BL/6 * CD-1 * FVB/N * SJL	MGI:5478604
cn16	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/? Tg(Pbsn-cre)4Prb/?	involves: 129X1/SvJ * C57BL/6 * DBA/2	MGI:3716207
cn17	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/? H2az2^Tg(Wnt1-cre)11Rth/H2az2^+	involves: 129X1/SvJ * C57BL/6J * CBA/J	MGI:3716199
cn18	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^+ H2az2^Tg(Wnt1-cre)11Rth/H2az2^+	involves: 129X1/SvJ * C57BL/6J * CBA/J	MGI:4843925
cn19	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc Tg(Krt1-5-cre/ERT)1Ipc/0	involves: 129X1/SvJ * C57BL/6 * SJL	MGI:4452397
cn20	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^+ Tg(Nes-cre)1Kln/0	involves: 129X1/SvJ * C57BL/6 * SJL	MGI:3844934
cn21	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^+ Tg(Pdgfra-cre/ERT)467Dbe/0	involves: 129X1/SvJ * C57BL/6 * SJL	MGI:6197799
cn22	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^+ Olig3^tm1(cre)Ynka/Olig3^+	involves: 129X1/SvJ * C57BL/6 * SJL	MGI:3844928
cn23	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc Tg(Atoh1-cre/Esr1*)14Fsh/0	involves: 129X1/SvJ * FVB/N	MGI:3810322
cn24	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc Tg(GFAP-cre)25Mes/0	involves: 129X1/SvJ * FVB/N	MGI:3810317
ot25	Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc/?	involves: 129X1/SvJ	MGI:3716205

Genotype
MGI:4420943

cn1

• Allelic Composition: Atoh1^tm3Hzo/Atoh1⁺; Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}
• Genetic Background: involves: 129 * 129S7/SvEvBrd * 129X1/SvJ

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

nervous system

abnormal neuronal precursor proliferation ( J:155047 )

• ectopic masses show numerous mitotic granule neuron precursors 10 days after tamoxifen treatment

abnormal cerebellum morphology ( J:155047 )

• 10 days after tamoxifen treatment, neoplastic and preneoplastic lesions in which the external granule layer lacks the normal layered structure develop in the external layer of the cerebellum

abnormal cerebellum external granule cell layer morphology ( J:155047 )

• hypertrophic 10 days after tamoxifen treatment

irregular external granule cell layer thickness ( J:155047 )

• 10 days after tamoxifen treatment, neoplastic and preneoplastic lesions in which the external granule layer lacks the normal layered structure develop in the external layer of the cerebellum

cellular

abnormal neuronal precursor proliferation ( J:155047 )

• ectopic masses show numerous mitotic granule neuron precursors 10 days after tamoxifen treatment

Genotype
MGI:4420935

cn2

• Allelic Composition: Atoh1^tm3Hzo/Atoh1^tm1Hzo; Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}
• Genetic Background: involves: 129 * 129S7/SvEvBrd * 129X1/SvJ

nervous system

abnormal neuronal precursor proliferation ( J:155047 )

• no cycling granule neuron precursor cells are detected in the external granule cell layer 10 days after tamoxifen treatment

thin external granule cell layer ( J:155047 )

• 10 days after tamoxifen treatment

cerebellum atrophy ( J:155047 )

• 10 days after tamoxifen treatment most mice have atrophic cerebella

cellular

abnormal neuronal precursor proliferation ( J:155047 )

• no cycling granule neuron precursor cells are detected in the external granule cell layer 10 days after tamoxifen treatment

Genotype
MGI:3810318

cn3

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}; Olig2^{tm2(TVA,cre)Rth}/Olig2⁺
• Genetic Background: involves: 129 * 129X1/SvJ

mortality/aging

premature death ( J:139574 )

• mice survive 33 days

neoplasm

increased medulloblastoma incidence ( J:139574 )

• mice develop focal medulloblastomas localized to the posterior-lateral lobes and have mean survival of 33 days

nervous system

increased medulloblastoma incidence ( J:139574 )

• mice develop focal medulloblastomas localized to the posterior-lateral lobes and have mean survival of 33 days

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
medulloblastoma		DOID:0050902	OMIM:155255	J:139574

Genotype
MGI:7616743

cn4

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor^{tm2(EGFP/cre)Alj}; Pgbd5^tm1.1Aken/Pgbd5^tm1.1Aken
• Genetic Background: involves: 129 * C57BL/6J * C57BL/6NTac * SW

neoplasm

increased medulloblastoma incidence ( J:346387 )

• develop tumors with a similar latency to mice with one wild-type Pgbd5 allele, but most tumors retain an unrecombined floxed Pgbd5 allele

nervous system

increased medulloblastoma incidence ( J:346387 )

• develop tumors with a similar latency to mice with one wild-type Pgbd5 allele, but most tumors retain an unrecombined floxed Pgbd5 allele

Genotype
MGI:5571383

cn5

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor⁺; Hk2^tm1.1Uku/Hk2^tm1.1Uku; Tg(GFAP-cre)25Mes/0
• Genetic Background: involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N

mortality/aging

premature death ( J:210113 )

• median survival is 31 days compared with mice with wild-type Hk2 that die by P20

neoplasm

abnormal tumor vascularization ( J:210113 )

• increased micro-vascularization

decreased tumor growth/size ( J:210113 )

• compared to in mice with wild-type Hk2

increased medulloblastoma incidence ( J:210113 )

• all mice develop tumors with reduced growth and at increased latency compared to in mice with wild-type Hk2

increased tumor latency ( J:210113 )

• all mice develop tumors with increased latency compared to in mice with wild-type Hk2

nervous system

abnormal neuronal precursor proliferation ( J:210113 )

• reduced cerebellar granule neuron progenitors proliferation

increased medulloblastoma incidence ( J:210113 )

• all mice develop tumors with reduced growth and at increased latency compared to in mice with wild-type Hk2

cellular

abnormal neuronal precursor proliferation ( J:210113 )

• reduced cerebellar granule neuron progenitors proliferation

cardiovascular system

abnormal tumor vascularization ( J:210113 )

• increased micro-vascularization

Genotype
MGI:5571384

cn6

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor⁺; Hk2^tm1.1Uku/Hk2⁺; Tg(GFAP-cre)25Mes/0
• Genetic Background: involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N

mortality/aging

premature death ( J:210113 )

• mice die by P20

neoplasm

increased medulloblastoma incidence ( J:210113 )

nervous system

increased medulloblastoma incidence ( J:210113 )

Genotype
MGI:3810321

cn7

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}; Shh^{tm2(cre/ERT2)Cjt}/Shh⁺
• Genetic Background: involves: 129S6/SvEvTac * 129X1/SvJ

neoplasm

neoplasm ( J:139574 )

N • following induction with tamoxifen, mice do not exhibit medulloblastoma

Genotype
MGI:3810320

cn8

• Allelic Composition: Gli1^{tm3(cre/ERT2)Alj}/Gli1⁺; Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}
• Genetic Background: involves: 129S6/SvEvTac * 129X1/SvJ

mortality/aging

premature death ( J:139574 )

• mice survive 45 days

neoplasm

increased medulloblastoma incidence ( J:139574 )

• all mice develop medulloblastomas that are located in lobes VI through IX and have a mean survival of 45 days

nervous system

increased medulloblastoma incidence ( J:139574 )

• all mice develop medulloblastomas that are located in lobes VI through IX and have a mean survival of 45 days

Genotype
MGI:6197800

cn9

• Allelic Composition: Gli1^{tm3(cre/ERT2)Alj}/Gli1⁺; Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S6/SvEvTac * 129X1/SvJ

respiratory system

respiratory system phenotype ( J:264185 )

N • tamoxifen-treated mice do not exhibit distal airspace morphological changes

Genotype
MGI:5518633

cn10

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor⁺; Nkx3-2^tm1(cre)Wez/Nkx3-2⁺
• Genetic Background: involves: 129S7/SvEvBrd * 129X1/SvJ

digestive/alimentary system

abnormal intestine development ( J:199664 )

• intestinal mesenchymal compartment is expanded

Genotype
MGI:6197802

cn11

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor⁺; Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0
• Genetic Background: involves: 129S/SvEv * 129X1/SvJ * C57BL/6

respiratory system

abnormal pulmonary alveolus morphology ( J:264185 )

• tamoxifen-treated lung mesenchymal fibroblasts cocultured with isolated SFTPC+ distal alveolar stem cells results in reduced distal alveolar organoid growth

Genotype
MGI:6197798

cn12

• Allelic Composition: Gli2^{tm1(cre/ERT2)Tipe}/Gli2⁺; Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129X1/SvJ

respiratory system

abnormal bronchioalveolar stem cell morphology ( J:264185 )

• alveolar stem cell renewal is disrupted, with tamoxifen-treated mice showing reduced fractions of SFTPC+ alveolar stem cells that incorporate BrdU during normal homeostasis and during injury with bleomycin

abnormal pulmonary alveolus morphology ( J:264185 )

• tamoxifen-treated mice show reduced density of alveoli in the distal lung

• tamoxifen-treated mice exhibit a more simplified alveolar structure in which secondary crests are absent from the enlarged alveoli

decreased type II pneumocyte number ( J:264185 )

• tamoxifen-treated mice show a loss of SFTPC+ type 2 pneumocytes from the distal alveolar region

overexpanded pulmonary alveolus ( J:264185 )

• tamoxifen-treated mice show enlarged alveolus size

emphysema ( J:264185 )

• tamoxifen-treated mice exhibit emphysematous changes in the alveolar airspace characterized by a 20% enlargement of airspace, increase in mean chord length, enlarged alveolus size, and reduced density of alveoli in the distal lung

• lungs of tamoxifen-treated mice show elevated low attenuation volume/total lung volume ratio, indicating airspace enlargement and emphysema

• however, no evidence of increased inflammatory cells or increased in the number of apoptotic cells in the lungs of tamoxifen-treated mice are seen

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
pulmonary emphysema		DOID:9675	OMIM:130700	J:264185

Genotype
MGI:3810319

cn13

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}; Tlx3^tm1(cre)Qima/Tlx3⁺
• Genetic Background: involves: 129X1/SvJ

mortality/aging

premature death ( J:139574 )

• mice survive 102 days

neoplasm

increased medulloblastoma incidence ( J:139574 )

• 40% of mice develop focal medulloblastomas and have a mean survival of 102 days

nervous system

increased medulloblastoma incidence ( J:139574 )

• 40% of mice develop focal medulloblastomas and have a mean survival of 102 days

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
medulloblastoma		DOID:0050902	OMIM:155255	J:139574

Genotype
MGI:3716204

cn14

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/?; Tg(CAG-cre/Esr1*)5Amc/?
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * CBA

mortality/aging

premature death ( J:114992 )

• following tamoxifen treatment, all mice are dead by 18 weeks of observation unlike untreated mice and Ptch1^tm1Mps heterozygotes

neoplasm

increased basal cell carcinoma incidence ( J:114992 )

• following tamoxifen treatment, mice exhibit macroscopic basal cell carcinomas (BBC) where as all other mice develop BBC tumors at 8 weeks

increased rhabdomyosarcoma incidence ( J:114992 )

• present without tamoxifen treatment (average number 3)

• following tamoxifen treatment, the multiplicity of tumors is increased (average number 7)

• mostly confined to rear thigh and abdominal wall

• following tamoxifen treatment, tumors are detected in skeletal muscle of the head, neck, tongue and paratesticular regions

• following tamoxifen treatment at P10, age of onset is accelerated to week 5 compared to week 9 in untreated mice

increased medulloblastoma incidence ( J:114992 )

• found in 27% of mice and 40% of mice following tamoxifen treatment

digestive/alimentary system

intestine polyps ( J:114992 )

• diverticular harmatomatous lesions in the intestine occur at a higher rate following treatment with tamoxifen (20% without treatment and 80% following treatment)

gastric polyps ( J:114992 )

• diverticular harmatomatous lesions in the stomach occur at a higher rate following treatment with tamoxifen (less than 5% of mice after treatment)

endocrine/exocrine glands

abnormal pancreas morphology ( J:114992 )

• cystic metaplastic lesions are observed with increased frequency following tamoxifen treatment

integument

increased basal cell carcinoma incidence ( J:114992 )

• following tamoxifen treatment, mice exhibit macroscopic basal cell carcinomas (BBC) where as all other mice develop BBC tumors at 8 weeks

nervous system

increased medulloblastoma incidence ( J:114992 )

• found in 27% of mice and 40% of mice following tamoxifen treatment

muscle

increased rhabdomyosarcoma incidence ( J:114992 )

• present without tamoxifen treatment (average number 3)

• following tamoxifen treatment, the multiplicity of tumors is increased (average number 7)

• mostly confined to rear thigh and abdominal wall

• following tamoxifen treatment, tumors are detected in skeletal muscle of the head, neck, tongue and paratesticular regions

• following tamoxifen treatment at P10, age of onset is accelerated to week 5 compared to week 9 in untreated mice

Genotype
MGI:5478604

cn15

• Allelic Composition: Cdcp1^tm1.2Moas/Cdcp1^tm1.2Moas; Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor⁺; Tg(KRT14-cre/ERT)20Efu/0
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * CD-1 * FVB/N * SJL

mortality/aging

premature death ( J:194368 )

• euthanized 12 weeks after tamoxifen-treatment

integument

focal hair loss ( J:194368 )

• in tamoxifen-treated mice, particularly evident on the abdominal skin

abnormal skin morphology ( J:194368 )

• tamoxifen-treated mice develop more severe epidermal disease (thick skin, hair loss and scaling) compared with control mice

thick epidermis ( J:194368 )

• 3.5-fold in tamoxifen-treated mice than in control mice

abnormal skin condition ( J:194368 )

• in tamoxifen-treated mice, particularly evident on the abdominal skin

thick skin ( J:194368 )

• in tamoxifen-treated mice

neoplasm

increased tumor growth/size ( J:194368 )

• accelerated neoplasm development in tamoxifen-treated mice compared with control mice

increased tumor incidence ( J:194368 )

• accelerated neoplasm development in tamoxifen-treated mice compared with control mice

behavior/neurological

hunched posture ( J:194368 )

• in tamoxifen-treated mice

Genotype
MGI:3716207

cn16

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/?; Tg(Pbsn-cre)4Prb/?
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * DBA/2

endocrine/exocrine glands

endocrine/exocrine gland phenotype ( J:114992 )

N • no increased hyperproliferative lesions or neoplastic transformation of the prostate are observed

Genotype
MGI:3716199

cn17

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/?; H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺
• Genetic Background: involves: 129X1/SvJ * C57BL/6J * CBA/J

growth/size/body

abnormal head development ( J:89445 )

• most of the head skeleton fails to form

abnormal face development ( J:89445 )

• at E10.5, facial processes are mildly hyperplastic

• at E12.5, gross organization of the face is disrupted

craniofacial

abnormal face development ( J:89445 )

• at E10.5, facial processes are mildly hyperplastic

• at E12.5, gross organization of the face is disrupted

Genotype
MGI:4843925

cn18

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor⁺; H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺
• Genetic Background: involves: 129X1/SvJ * C57BL/6J * CBA/J

mortality/aging

embryonic lethality during organogenesis, incomplete penetrance ( J:135134 )

• half of mice die at E11.5

embryo

increased cardiac neural crest cell number ( J:135134 )

• the number of cardiac neural crest cells is increased in the cardiac jelly compared to in wild-type mice

cardiovascular system

increased cardiac neural crest cell number ( J:135134 )

• the number of cardiac neural crest cells is increased in the cardiac jelly compared to in wild-type mice

abnormal cardiac outflow tract development ( J:135134 )

• at E11.5, surviving mice exhibit a lack of cushions in the distal outflow tract while more proximal outflow tract cushions are closer to each other unlike in wild-type mice

persistent truncus arteriosus ( J:135134 )

• at E15.5

nervous system

increased cardiac neural crest cell number ( J:135134 )

• the number of cardiac neural crest cells is increased in the cardiac jelly compared to in wild-type mice

Genotype
MGI:4452397

cn19

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}; Tg(Krt1-5-cre/ERT)1Ipc/0
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * SJL

neoplasm

increased basal cell carcinoma incidence ( J:158915 )

• tamoxifen-treated mice develop basal cell carcinomas that are restricted to the epidermis

integument

increased basal cell carcinoma incidence ( J:158915 )

• tamoxifen-treated mice develop basal cell carcinomas that are restricted to the epidermis

Genotype
MGI:3844934

cn20

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor⁺; Tg(Nes-cre)1Kln/0
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * SJL

mortality/aging

neonatal lethality, complete penetrance ( J:147427 )

• animals die by the end of the first postnatal day (P0)

nervous system

increased brain size ( J:147427 )

• in all embryos, brain size is larger than in controls, especially in the dorsal telencephalon

abnormal thalamus morphology ( J:147427 )

• based on cell fate analysis and molecular marker analysis, the intergeniculate leaflet (IGL) nucleus is expanded caudodorsally along the surface of the diencephalon at E16.5

abnormal lateral geniculate nucleus morphology ( J:147427 )

• based on cell fate analysis and molecular marker analysis, the dorsal lateral geniculate (dLG) nucleus is expanded caudodorsally along the surface of the diencephalon at E16.5

Genotype
MGI:6197799

cn21

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor⁺; Tg(Pdgfra-cre/ERT)467Dbe/0
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * SJL

respiratory system

abnormal pulmonary alveolus morphology ( J:264185 )

• tamoxifen-treated mice show reduced density of alveoli

overexpanded pulmonary alveolus ( J:264185 )

• alveoli are enlarged in tamoxifen-treated mice

emphysema ( J:264185 )

• tamoxifen-treated mice exhibit emphysematous changes including enlarged alveoli with reduced alveolar density

Genotype
MGI:3844928

cn22

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor⁺; Olig3^tm1(cre)Ynka/Olig3⁺
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * SJL

mortality/aging

prenatal lethality, incomplete penetrance ( J:147427 )

• partial; some pups survive postnatally

nervous system

nervous system phenotype ( J:147427 )

N • brains are morphologically indistinguishable from controls

abnormal thalamus morphology ( J:147427 )

• expansion of the expression domain of the orphan receptor ROR alpha indicates that the the ventral posterior nucleus (VP) is increased in size

• in E18.5 brains, molecular marker analysis indicates that the entire postmitotic thalamus exhibits rostroventral identity

abnormal lateral geniculate nucleus morphology ( J:147427 )

• based on thalamic labeling by cholera toxin B subunit injection, the volume of the dorsal lateral geniculate nucleus (dLG) is increased more than 3-fold compared to control neonatal animals; expansion of the expression domain of the orphan receptor ROR alpha indicates that the dLG is increased in size

Genotype
MGI:3810322

cn23

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}; Tg(Atoh1-cre/Esr1*)14Fsh/0
• Genetic Background: involves: 129X1/SvJ * FVB/N

mortality/aging

premature death ( J:139574 )

• mice survive 41 days

nervous system

increased medulloblastoma incidence ( J:139574 )

• all mice develop diffuse medulloblastomas and have a mean survival of 41 days

abnormal cerebellum external granule cell layer morphology ( J:139574 )

• mice exhibit hyperplasia on the external granule cell layer beginning at P0 and more prominently at P7

neoplasm

increased medulloblastoma incidence ( J:139574 )

• all mice develop diffuse medulloblastomas and have a mean survival of 41 days

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
medulloblastoma		DOID:0050902	OMIM:155255	J:139574

Genotype
MGI:3810317

cn24

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}; Tg(GFAP-cre)25Mes/0
• Genetic Background: involves: 129X1/SvJ * FVB/N

mortality/aging

premature death ( J:139574 )

• mice survive 57 days

neoplasm

increased medulloblastoma incidence ( J:139574 )

• mice develop diffuse medulloblastoma tumors and have a mean survival of 57 days

nervous system

increased medulloblastoma incidence ( J:139574 )

• mice develop diffuse medulloblastoma tumors and have a mean survival of 57 days

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
medulloblastoma		DOID:0050902	OMIM:155255	J:139574

Genotype
MGI:3716205

ot25

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Smo/EYFP)Amc}/?
• Genetic Background: involves: 129X1/SvJ

neoplasm

neoplasm ( J:114992 )

N • no tumors are observed up to 12 months of age